



# Role of ferritin and oxidative stress index in gestational diabetes mellitus

Surabhi Gautam<sup>1</sup> · Feroz Alam<sup>1</sup> · Shagufta Moin<sup>2</sup> · Nasreen Noor<sup>3</sup> · S. H. Arif<sup>1</sup>

Received: 13 July 2021 / Accepted: 25 September 2021 / Published online: 1 October 2021  
© Springer Nature Switzerland AG 2021

## Abstract

**Objectives** To investigate the role of serum ferritin and oxidative stress in the development of GDM and to assess their relationship with the ensuing hyperglycemia.

**Methods** A case–control study was carried on 90 non-anemic pregnant women of 20–40 years with a gestation of 24–28 weeks. Study group (n = 65) was identified according to the Diabetes in Pregnancy Study Group India (DIPSI) criteria (2-h plasma glucose  $\geq$  140 mg/dl) and controls (n = 25) having 2-h plasma glucose < 120 mg/dl. DIPSI 2-h plasma glucose, HbA1c and serum ferritin were measured and oxidative stress index (OSI) was calculated. Statistical tests were performed using SPSS version 25.0.

**Results** Pre-pregnancy BMI showed a significant difference between control and study group. DIPSI 2 h blood glucose, HbA1c, serum ferritin and OSI were significantly higher in study group compared to control group. Both 2 h blood glucose and HbA1c were positively correlated with serum ferritin and OSI, serum ferritin and OSI were also positively correlated with each other.

**Conclusion** Higher pre-pregnancy BMI elevates serum ferritin, which in turn increases the OSI. Both ferritin and oxidative stress raises 2 h blood glucose and HbA1c in GDM patients possibly by causing in-vivo pancreatic  $\beta$ -cell injury and death (ferroptosis). Serum ferritin and OSI could become newer personalized theranostic and monitoring targets in overweight/obese pregnant females especially GDM patients.

**Keywords** Ferritin · Oxidative Stress Index · Gestational Diabetes Mellitus · Fenton reaction · Ferroptosis

## Introduction

Gestational diabetes mellitus (GDM) is usually defined as a varying degree of glucose intolerance having either its onset or first recognition during pregnancy. GDM is estimated to affect 14% of pregnancies worldwide, accounting for about 18.4 million births annually [1]. A recent

study suggests that GDM may affect between 5–8 million pregnant women in India annually [2]. Primarily, GDM develops when insulin secretion fails to overcome the pregnancy induced physiologic insulin resistance (IR). Genetic, epigenetic, and environmental factors may all contribute to the development of GDM; there is evidence of adipose expandability, low-grade chronic inflammation, gluconeogenesis, oxidative stress, and some placental factors contributing to the pathogenesis of GDM [3]. GDM may lead to both fetal and maternal complications, but still there is no uniform criterion to diagnose GDM. The frequently recommended guideline is that of the International Association of Diabetes in Pregnancy Study Group (IADPSG), but its importance is declining nowadays because it lacks standardization and needs revision. A simple test with 75-g oral glucose load to a pregnant female in either fasting or non-fasting state, having a 2-h plasma glucose value of  $\geq$  7.8 mmol/dl ( $\geq$  140 mg/dl) was seen to detect GDM successfully. The Diabetes in Pregnancy

✉ Feroz Alam  
ferozalam97@gmail.com

<sup>1</sup> Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, UP, India

<sup>2</sup> Department of Biochemistry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, UP, India

<sup>3</sup> Department of Obstetrics & Gynaecology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, UP, India

Study Group India (DIPSI) has accepted this “single test procedure” to diagnose GDM. The National Institute of Clinical Excellence (NICE) guidelines also recommend 2-h PG  $\geq 7.8$  mmol/dl as one of the diagnostic criteria for GDM. This doable procedure is approved by the Ministry of Health & Family Welfare Government of India, WHO, FIGO, and IDF [4].

Iron is an essential trace element and its deficiency or excess may lead to abnormalities. Excessive iron stores have been implicated in the development of type 2 diabetes by damaging the pancreatic  $\beta$ -cells and causing insulin resistance [5]. Iron is stored in the body as ferritin, and measurement of ferritin in serum reflects adequately the pool of iron present in bone marrow macrophages. Ferritin is also an acute phase reactant and it is increased in many chronic diseases and inflammation. Increased cellular ferritin has been linked to pancreatic  $\beta$ -cell dysfunction and insulin resistance. Ferritin levels are elevated in type 2 diabetes patients, and increased serum ferritin levels in Western and Asian population were associated with an increased risk of diabetes [6]. The elevated serum ferritin might interact with other genetic and environmental factors, impairing  $\beta$ -cells functioning and affecting insulin secretion [7]. The raised iron leads to oxidative stress in the body further aggravating insulin resistance and hyperglycemia [8].

Oxidative stress (OS) is an imbalance between cellular pro-oxidant and antioxidant level, there is production and accumulation of reactive oxygen species (ROS) in cells. ROS are described as free radical and non-radical derivatives of oxygen, and include superoxide anion ( $O_2^-$ ), hydroxyl radical ( $\bullet OH$ ) and hydrogen peroxide ( $H_2O_2$ ) [9]. Damage of cellular proteins, lipids and DNA by ROS leads to oxidative stress, and has been implicated in the pathogenesis of many diseases, including GDM [10]. Women with GDM are known to overproduce free radicals in addition to an impaired free-radical scavenging mechanism [11]. ROS also inhibit insulin-stimulated glucose uptake at the molecular level by interfering with insulin receptors [12], and ROS also reduces glycogen synthesis in the liver and muscle. Iron supplementation in pregnant women having adequate iron stores, is associated with the development of GDM [13]. It has been established that this effect of iron is mainly due to the increased oxidative stress as iron can catalyze the reaction from  $O_2^-$  and  $H_2O_2$  to the extremely reactive  $\bullet OH$  (Fenton reaction) [14]. Ferritin responds to oxidative stress, however, controversy exists whether ferritin has pro- or antioxidant properties. Superoxide can mobilize stored iron from ferritin, increasing the pool of reactive iron and exacerbating oxidative stress [15]. Therefore, serum ferritin may have a direct role in the development and progression of GDM mediated via the oxidative damage mechanism. The present study attempts to seek a direct evidence of this mechanism in pregnant females.

## Subjects, materials and methods

### Study design

A 2 years prospective case–control study from 2018 to 2020 was carried in the Department of Pathology, Department of Biochemistry and Department of Obstetrics and Gynaecology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh. Ethical clearance was obtained from the Institutional Ethical Committee. The participants were informed of all possible expected benefits and harms ensuing from the study and written consent was taken from the participants before enrolling them in the study.

### Study participants and measures

Relevant history & detailed physical examination along with laboratory analysis was performed. 20–40 years old non-anemic pregnant women having a gestational age of 24–28 weeks, diagnosed with gestational diabetes mellitus (DIPSI  $\geq 140$  mg/dl) were included in the study group ( $n = 65$ ). Age matched non-anemic, non-overweight/obese and euglycemic (DIPSI  $< 120$  mg/dl) pregnant women having a gestational age of 24–28 weeks, who were apparently normal comprised the control Group ( $n = 25$ ).

### Inclusion and exclusion criteria

All consenting pregnant females diagnosed with GDM were included in the study. Exclusion Criteria were non-consenting females, females with a family history of diabetes mellitus, patients with (diabetes, hypertension, polycystic ovarian syndrome), patients with iron deficiency anemia, patients with acute or chronic (liver, kidney, heart, lung, thyroid) diseases, patients with acute or chronic inflammatory diseases, patients with infective diseases, patients with known malignancy and patients with seizure disorders.

### Measurements

After the informed consent, detailed history and clinical examination, the blood samples were withdrawn from the subjects. Oral glucose tolerance test (OGTT) was performed according to the DIPSI criteria with 75 g oral glucose in non-fasting state and 2 ml blood was collected in sodium fluoride vial for estimation of blood glucose by glucose oxidase method, 2 ml of blood in EDTA vial was used for HbA1c estimation by HPLC. Lastly, 2 ml blood in plain vial was collected for serum Ferritin (ELISA, Calbiotech Inc.) and Total Oxidant Status (TOS, SRL, India) & Total Antioxidant Status (TAS, Sigma Aldrich) measurement

spectrophotometrically. The oxidative stress index (OSI) was calculated as the ratio of the TOS level to TAS level, as had been described earlier [16].

### Statistical analysis

All the statistical tests were performed using computer program SPSS version 25.0. Descriptive analysis was done by percentages and Mean  $\pm$  SD (standard deviation). To test the significance of two means, the student's 't' test was used; a p value  $< 0.05$  was taken as significant. Pearson Chi Square test was used to analyze all the qualitative variables. All the quantitative variables were analyzed using Independent Sample t-test. Pearson Moment Correlation Analysis was also used to look for any correlation among different variables, correlation coefficient "r" between 0.4–0.7 was taken as moderate correlation, and r between 0.7–0.9 was high correlation.

### Results

Body mass index (BMI) was classified as normal (18.5–24.9 kg/m<sup>2</sup>), overweight (25–29.9 kg/m<sup>2</sup>) and obese ( $> 30$  kg/m<sup>2</sup>). Pre-pregnancy BMI among control group was  $23.86 \pm 1.55$  kg/m<sup>2</sup> while in study group it was  $27.54 \pm 2.50$  kg/m<sup>2</sup>, the 'p' value ( $< 0.001$ ) came out to be statistically significant. Mean  $\pm$  SD of 2 h glucose after 75 g load was  $85.26 \pm 4.49$  mg/dl in control group while in study group it was  $178.03 \pm 13.03$  mg/dl, p value ( $< 0.001$ ) was statistically significant. The Mean  $\pm$  SD hemoglobin concentration of study group was  $11.68 \pm 0.56$  g % while of control group was  $11.88 \pm 0.67$  g %, p ( $> 0.05$ ) was statistically insignificant. All women in control group had HbA1c in the normal range (4–5.6%) whereas in study group 66% women had HbA1c in pre-diabetic range (5.7–6.4%) and 34% women in the diabetic range ( $> 6.5\%$ ). The Mean  $\pm$  SD HbA1c among control group was  $5.16 \pm 0.25\%$  while in study group it was  $6.39 \pm 0.43\%$ , p value ( $< 0.001$ ) was statistically significant. Serum ferritin among women in control group was mostly  $< 30$  ng/ml while serum ferritin among study group was mostly  $> 85$  ng/ml. Mean  $\pm$  SD serum ferritin among controls was  $32.44 \pm 4.49$  ng/dl while among

study group it was  $78.11 \pm 35.38$  ng/dl, p value ( $< 0.001$ ) was statistically significant. Hence, higher levels of serum ferritin were seen in GDM patients. Mean  $\pm$  SD of TOS among controls was  $2.78 \pm 1.26$   $\mu\text{mol H}_2\text{O}_2$  Eq/L while among study group it was  $10.18 \pm 4.53$   $\mu\text{mol H}_2\text{O}_2$  Eq/L, p value ( $< 0.001$ ) was statistically significant. Mean  $\pm$  SD TAS of controls was  $3.95 \pm 0.92$   $\mu\text{mol Trolox Eq/L}$  and in study group it was  $2.10 \pm 0.69$   $\mu\text{mol Trolox Eq/L}$ , p value ( $< 0.001$ ) was statistically significant. OSI among controls was  $0.81 \pm 0.62$  while in the study group it was  $5.40 \pm 3.02$ , p value ( $< 0.001$ ) was statistically significant. Table 1 compares the above mentioned variables in the control and the study group. 2 h blood glucose was positively correlated with serum ferritin ( $r = +0.526$ ,  $p < 0.01$ ) and OSI ( $r = +0.581$ ,  $p < 0.01$ ), HbA1c was positively correlated with serum ferritin ( $r = +0.438$ ,  $p < 0.01$ ) and OSI ( $r = +0.502$ ,  $p < 0.01$ ). Serum ferritin and OSI were also positively correlated with each other ( $r = +0.406$ ,  $p < 0.01$ ), Table 2.

### Discussion

Overweight or obese females had an increased risk of GDM compared to lean or normal-weight females. Women having a pre-pregnancy BMI over 30 have been shown to be 3-times more at risk of developing GDM compared to women with normal pre-pregnancy BMI [17]. Obese pregnant women show major metabolic derangements, and may have up to 40% higher insulin resistance compared to normal weight women [18]. Inflammation is another possible mechanism linking obesity with GDM, adipocytes secrete pro-inflammatory cytokines which may have a role in the development of GDM [17]. Weight management through nutritional

**Table 2** Correlation of S. Ferritin and OSI with 2-h glucose, HbA1c and amongst them

|                  | S. Ferritin (Correlation coefficient, r) | OSI (Correlation coefficient, r) |
|------------------|--|----------------------------------|
| GST- 2 h glucose | .526; $p < .01$                          | .581; $p < .01$                  |
| HbA1c            | .438, $p < .01$                          | .502, $p < .01$                  |
| S. Ferritin      | -  | .406, $p < .01$                  |

**Table 1** Comparison of different variables between the control and study groups

|            | BMI (Kg/m <sup>2</sup> ) | 2-h Glucose (mg/dl) | HbA1c (%)       | Serum Ferritin (ng/dl) | TOS ( $\mu\text{mol H}_2\text{O}_2$ Eq/L) | TAS ( $\mu\text{mol Trolox Eq/L}$ ) | OSI             |
|------------|--------------------------|---------------------|-----------------|------------------------|---|-------------------------------------|-----------------|
| Control gp | $23.86 \pm 1.55$         | $85.26 \pm 4.49$    | $5.16 \pm 0.25$ | $32.44 \pm 4.49$       | $2.78 \pm 1.26$                           | $3.95 \pm 0.92$                     | $0.81 \pm 0.62$ |
| Study gp   | $27.54 \pm 2.50$         | $178.03 \pm 13.03$  | $6.39 \pm 0.43$ | $78.11 \pm 35.38$      | $10.18 \pm 4.53$                          | $2.10 \pm 0.69$                     | $5.40 \pm 3.02$ |
| t- value   | -6.865                   | -34.701             | -13.589         | -6.412                 | -8.032                                    | 10.364                              | -7.518          |
| p-value    | $p < .001$               | $p < .001$          | $p < .001$      | $p < .001$             | $p < .001$                                | $p < .001$                          | $p < .001$      |

prevention strategies could be successful in reducing the risk of GDM [19]. In the present study it was evident that raised pre-pregnancy BMI was significantly related with GDM, similar results were seen in other studies also [20].

As expected, in our study the DIPSI 2 h blood glucose showed significant difference in the study and control group, similar findings were seen in other studies also [21]. HbA1c in control group was well within the normal range; in the study group 66% women had HbA1c in the pre-diabetic range, while 34% women had HbA1c in the diabetic range. Hence, even in the study group majority of women had only mildly increased glycosylated hemoglobin. Similar results were seen in other study where majority of GDM patients had HbA1c levels in the pre-diabetic range only [21]. Similarly, Kwon et al. found a mean HbA1c level in the normal pregnant women to be significantly lower than GDM patients [22]. The first-trimester HbA1c level is a reliable predictor of complications during pregnancy, but the physiological changes occurring during pregnancy prevents the use of HbA1c for diagnosing GDM [23]. However, HbA1c could be used as a risk predictor of future type 2 DM development in patients of GDM.

Obesity causes a state of sub-clinical inflammation, compression of adipocyte by stored fat causes cellular hypoxia and releasing inflammatory cytokines and chemokines. Pro-inflammatory mediators are also released by obesity activated leukocytes, macrophages and lymphocytes [24, 25]. It has been shown that high levels of ferritin were positively correlated with the risk of metabolic syndrome, obesity and inflammatory marker CRP [26, 27]. In overweight and obese people, ferritin is more a marker of on-going inflammation rather than iron stores [28]. A recent study indicates that excessive adiposity is associated with elevated serum ferritin and hepcidin independent of dietary intake [29]. The ferritin originates from an injured cell, losing most of its iron and leaving this iron in a highly reactive un-liganded form (hydroxyl radicals production via Fenton reaction) [30]. Further, the un-liganded ferrous ( $\text{Fe}^{2+}$ ) iron causes lipid peroxidation and ROS production, which can trigger ferroptosis. Pancreatic beta-cells with low expression of antioxidant enzymes are predisposed to ferroptotic cell death. Indeed, experimental evidence had suggested that pharmacologically induced ferroptosis can lead to impaired islet function and viability of human pancreatic islets [31]. In our study, we have found that serum ferritin and OSI among study group was significantly higher than controls, similar findings have also been shown very recently by Feng et al. [32]. Quercetin (flavonoid anti-oxidant) achieved normal  $\beta$ -cell function through amelioration of ferroptosis in T2DM [33]. Lately, evidences have started gathering that ferroptosis may play a critical role in the causation of chronic complications associated with diabetes mellitus like diabetic nephropathy [34], diabetes related cardiac events [35] and endothelial

dysfunction [36]. This study also adds to the evidence that ferritin induced oxidative damage leads to poor glycemic control in GDM which possibly results due to cell injury/ferroptosis of pancreatic  $\beta$ -cells.

## Conclusion

Raised pre-pregnancy BMI increases serum ferritin and OSI predisposing to GDM. The un-liganded, hyper-reactive ferritin leads to generation of ROS via the Fenton reaction; ferritin and oxidative damage both are possibly responsible for pancreatic  $\beta$ -cell injury and death (ferroptosis) which is clinically reflected as increasing 2-h glucose and HbA1c levels in GDM. Targeting ferritin and the induced changes at multiple molecular levels along with re-enforcing the antioxidant mechanisms would play significant role in future management of GDM.

**Acknowledgements** Nil

**Declarations**

The authors will go ahead with the subscription publication route.

**Source(s) of support** Nil.

**Presentation at a meeting** Nil.

**Conflict of interest** Nil.

## References

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract.* 2018;138:271–81. <https://doi.org/10.1016/j.diabres.2018.02.023>.
2. Swaminathan G, Swaminathan A, Corsi DJ. Prevalence of Gestational Diabetes in India by Individual Socioeconomic, Demographic, and Clinical Factors. *JAMA Netw Open.* 2020;3(11):e2025074. <https://doi.org/10.1001/jamanetworkopen.2020.25074>.
3. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. *Int J Mol Sci.* 2018;19:3342. <https://doi.org/10.3390/ijms19113342>.
4. Seshiah V, Balaji V, Banerjee S, Sahay R, Divakar H, Jain R, et al. Diagnosis and principles of management of gestational diabetes mellitus in the prevailing COVID-19 pandemic. *Int J Diabetes Dev Ctries.* 2020;40:329–34. <https://doi.org/10.1007/s13410-020-00860-1>.
5. Bertelsen M, Anggard EE, Carrier MJ. Oxidative stress impairs insulin internalization in endothelial cells in vitro. *Diabetologia.* 2001;44:605–13.
6. Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: A meta-analysis and systematic review. *J Diabetes Investig.* 2020;11:946–55.

7. Cooksey RC, Jouihan HA, Ajioka RS, et al. Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. *Endocrinology*. 2004;145:5305–12.
8. Zhuang T, Han H, Yang Z. Iron, oxidative stress and gestational diabetes. *Nutrients*. 2014;6:3968–80.
9. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev*. 2017;2017:8416763. <https://doi.org/10.1155/2017/8416763>.
10. Lappas M, Hiden U, Desoye G, Froehlich J, Hauguel-de Mouzon S, Jawerbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. *Antioxid Redox Signal*. 2011;15:3061–100.
11. Zhu C, Yang H, Geng Q, Ma Q, Long Y, Zhou C, Chen M. Association of oxidative stress biomarkers with gestational diabetes mellitus in pregnant women: A case-control study. *PLoS ONE*. 2015;10:e0126490.
12. Pessler D, Rudich A, Bashan N. Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter. *Diabetologia*. 2001;44:2156–64.
13. Javadian P, Alimohamadi S, Gharedaghi MH, Hantoushzadeh S. Gestational diabetes mellitus and iron supplement; effects on pregnancy outcome. *Acta Med Iran*. 2014;52:385–9.
14. Puntarulo S. Iron, oxidative stress and human health. *Mol Asp Med*. 2005;26:299–312.
15. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. *Free Radic Biol Med*. 2002;33:457–63.
16. Motor S, Ozturk S, Ozcan O, Gurpinar AB, Can Y, Yuksel R, et al. Evaluation of total antioxidant status, total oxidant status and oxidative stress index in patients with alopecia areata. *Int J Clin Exp Med*. 2014;7:1089–93.
17. Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. *Obes Rev*. 2009;10:194–203.
18. Sivan E, Chen X, Homko CJ, Reece EA, Boden G. Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. *Diabetes Care*. 1997;20:1470–5.
19. Morisset AS, St-Yves A, Veillette J, Weisnagel SJ, Tchernof A, Robitaille J. Prevention of gestational diabetes mellitus: a review of studies on weight management. *Diabetes Metab Res Rev*. 2010;26:17–25. <https://doi.org/10.1002/dmrr.1053>.
20. Machado C, Monteiro S, Oliveria MJ. Impact of overweight and obesity on pregnancy outcomes in women with gestational diabetes – results from a retrospective multicenter study. *Arch Endocrinol Metab*. 2020;64(1). <https://doi.org/10.20945/2359-399700000178>.
21. Shrivastava N, Durugkar K, Viswanadh P, Bal H. The study of role of HbA1c as a predictor of gestational diabetes mellitus. *Int J Reprod Contracept Obstet Gynecol*. 2019;8:4525–30.
22. Kwon SS, Kwon JY, Park YW, Kim YH, Lim JB. HbA1c for diagnosis and prognosis of gestational diabetes mellitus. *Diabetes Res Clin Pract*. 2015;110:38–43.
23. Sun J, Chai S, Zhao X, Yuan N, Du J, Liu Y, et al. Predictive value of first trimester glycosylated hemoglobin levels in gestational diabetes mellitus: A Chinese population cohort study. *J Diab Res*. 2021. <https://doi.org/10.1155/2021/5537110>.
24. Vehapoglu A, Turkmen S, Goknar N, Ozer OF. Reduced antioxidant capacity and increased subclinical inflammation markers in prepubescent obese children and their relationship with nutritional markers and metabolic parameters. *Redox Rep*. 2016;21:271–80.
25. Rogero MM, Calder PC. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. *Nutrients*. 2018;30(10):432. <https://doi.org/10.3390/nu10040432>.
26. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in mexican american men— the third national health and nutrition examination survey. *Int J Obes*. 2001;25:639–45.
27. Alam F, Fatima F, Orakzai S, Iqbal NT, Fatima SS. Elevated levels of ferritin and hs-CRP in type 2 diabetes. *J Pak Med Assoc*. 2014;64:1389–91.
28. Khan A, Khan WM, Ayub M, Humayun M, Haroon M. Ferritin Is a Marker of Inflammation rather than Iron Deficiency in Overweight and Obese People. *J Obes*. 2016;2016:1937320. <https://doi.org/10.1155/2016/1937320>.
29. Heslin AM, Donnell AO, Buffini M, Nugent A, Walton J, Flynn A, et al. Excessive adiposity is associated with an inflammation induced elevation in serum hepcidin, serum ferritin and increased risk of iron overload. *Proc Nutr Soc*. 2020;79(OCE2):E642. <https://doi.org/10.1017/S0029665120005911>.
30. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. *Arch Toxicol*. 2010;84:825–89. <https://doi.org/10.1007/s00204-010-0577-x>.
31. Bruni A, Pepper AR, Pawlick RL, Gala-Lopez B, Gamble A, Kin T, et al. Ferroptosis-inducing agents compromise in vitro human islet viability and function. *Cell Death Dis*. 2018;9:595. <https://doi.org/10.1038/s41419-018-0506-0>.
32. Feng Y, Feng Q, Lv Y, Song X, Qu H, Chen Y. The relationship between iron metabolism, stress hormones, and insulin resistance in gestational diabetes mellitus. *Nutr Diabetes*. 2020;10:17. <https://doi.org/10.1038/s41387-020-0122-9>.
33. Li D, Jiang C, Mei G, Zhao Y, Li C, Liu J, et al. Quercetin Alleviates Ferroptosis of Pancreatic  $\beta$  Cells in Type 2 Diabetes. *Nutrients*. 2020;12:2954. <https://doi.org/10.3390/nu12102954>.
34. Feng X, Wang S, Sun Z, Dong H, Yu H, Huang M, et al. Ferroptosis Enhanced Diabetic Renal Tubular Injury via HIF-1 $\alpha$ /HO-1 Pathway in db/db Mice. *Front Endocrinol*. 12:art no. 626390. <https://doi.org/10.3389/fendo.2021.626390>.
35. Sha W, Hu F, Xi Y, Chu Y, Bu S. Mechanism of Ferroptosis and its Role in Type 2 Diabetes Mellitus. *J Diabetes Res*. 2021:1–10. <https://doi.org/10.1155/2021/9999612>.
36. Luo EF, Li HX, Qin YH, Qiao Y, Yan GL, Yao YY, et al. Role of ferroptosis in the process of diabetes-induced endothelial dysfunction. *World J Diabetes*. 2021;12:124–37.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.